Tag Archive for: European Biotech

CONNECTA Therapeutics and Centre for Genomic Regulation to Present First-in-Class Program CTH120 for Fragile X Syndrome at FENS Forum 2026

/in

Preclinical data highlight restoration of cognitive, behavioral and synaptic deficits in Fragile X syndrome models Barcelona, Spain – 2 July 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in central nervous system (CNS) disorders, today announced that it will present a poster, together with the Centre […]

Read more

CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome

/in

Builds on positive Phase I safety data and represents a key value-inflection milestone for the Company Advances a potentially disease-modifying approach for fragile X syndrome, a condition with no approved targeted therapies Barcelona, Spain – 10 June 2026 – CONNECTA Therapeutics, a clinical-stage biotech company pioneering first-in-class neuroplasticity modulators to address unmet medical needs in […]

Read more

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

/in

Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer Financing supports Ona’s transition […]

Read more

BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair

/in

Seasoned life science investor, executive and board leader to support next phase of growth as BOOST Pharma advances BT-101, a promising and potentially disease-modifying therapy for osteogenesis imperfecta Stockholm, Sweden, March 19, 2026 – BOOST Pharma (“BOOST” or the “Company), a clinical‑stage biopharmaceutical company developing novel, first‑in‑class off-the-shelf cell therapies for rare, debilitating pediatric skeletal […]

Read more

Sanofi offers to acquire Kiadis for €308 million

/in

Congratulations to Kiadis Pharma on recently announcing that it is being acquired by Sanofi in a deal valued at approximately €308m ($359m), a 272% premium over last week’s closing price, one of the largest premiums in European biotech. After the discontinuation of its lead product candidate and subsequent reorganization in 2019, Kiadis started 2020 as an entirely new company […]

Read more
© Optimum Strategic Communications.